These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 21045017

  • 1. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
    Wang P, Wu F, Zhang J, McMullen T, Young LC, Ingham RJ, Li L, Lai R.
    Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
    [Abstract] [Full Text] [Related]

  • 2. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 3. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M, Kasprzycka M, Liu X, Raghunath PN, Wlodarski P, Wasik MA.
    Oncogene; 2007 Feb 08; 26(6):813-21. PubMed ID: 16909118
    [Abstract] [Full Text] [Related]

  • 4. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
    Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, Wasik MA, Morris SW, Skorski T.
    Cancer Res; 2001 Sep 01; 61(17):6517-23. PubMed ID: 11522649
    [Abstract] [Full Text] [Related]

  • 5. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis.
    Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA, Skorski T.
    Cancer Res; 2001 Mar 01; 61(5):2194-9. PubMed ID: 11280786
    [Abstract] [Full Text] [Related]

  • 6. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.
    Turner SD, Tooze R, Maclennan K, Alexander DR.
    Oncogene; 2003 Oct 30; 22(49):7750-61. PubMed ID: 14586401
    [Abstract] [Full Text] [Related]

  • 7. Identification of a novel crosstalk between casein kinase 2α and NPM-ALK in ALK-positive anaplastic large cell lymphoma.
    Armanious H, Gelebart P, Anand M, Lai R.
    Cell Signal; 2013 Feb 30; 25(2):381-8. PubMed ID: 23153582
    [Abstract] [Full Text] [Related]

  • 8. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
    Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS.
    Oncogene; 2004 Apr 08; 23(15):2617-29. PubMed ID: 14968112
    [Abstract] [Full Text] [Related]

  • 9. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
    Turturro F, Arnold MD, Frist AY, Pulford K.
    Clin Cancer Res; 2002 Jan 08; 8(1):240-5. PubMed ID: 11801565
    [Abstract] [Full Text] [Related]

  • 10. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY, Johnston PB, Burke KA, Zhao Y.
    Cancer Res; 2006 Sep 15; 66(18):9002-8. PubMed ID: 16982741
    [Abstract] [Full Text] [Related]

  • 11. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
    Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA.
    Biochemistry; 2005 Jun 14; 44(23):8533-42. PubMed ID: 15938644
    [Abstract] [Full Text] [Related]

  • 12. Immunohistochemical screening for oncogenic tyrosine kinase activation.
    Pulford K, Delsol G, Roncador G, Biddolph S, Jones M, Mason DY.
    J Pathol; 1999 Apr 14; 187(5):588-93. PubMed ID: 10398126
    [Abstract] [Full Text] [Related]

  • 13. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions.
    Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R.
    J Biol Chem; 2010 Jun 25; 285(26):19813-20. PubMed ID: 20424160
    [Abstract] [Full Text] [Related]

  • 14. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation.
    Chikamori M, Fujimoto J, Tokai-Nishizumi N, Yamamoto T.
    Oncogene; 2007 May 03; 26(20):2950-4. PubMed ID: 17086210
    [Abstract] [Full Text] [Related]

  • 15. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
    Thornber K, Colomba A, Ceccato L, Delsol G, Payrastre B, Gaits-Iacovoni F.
    Oncogene; 2009 Jul 23; 28(29):2690-6. PubMed ID: 19503098
    [Abstract] [Full Text] [Related]

  • 16. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R.
    Oncogene; 2004 Jul 15; 23(32):5426-34. PubMed ID: 15184887
    [Abstract] [Full Text] [Related]

  • 17. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors.
    Lu L, Ghose AK, Quail MR, Albom MS, Durkin JT, Holskin BP, Angeles TS, Meyer SL, Ruggeri BA, Cheng M.
    Biochemistry; 2009 Apr 28; 48(16):3600-9. PubMed ID: 19249873
    [Abstract] [Full Text] [Related]

  • 18. Functional characterization of the kinase activation loop in nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) using tandem affinity purification and liquid chromatography-mass spectrometry.
    Wang P, Wu F, Ma Y, Li L, Lai R, Young LC.
    J Biol Chem; 2010 Jan 01; 285(1):95-103. PubMed ID: 19887368
    [Abstract] [Full Text] [Related]

  • 19. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
    Greenland C, Touriol C, Chevillard G, Morris SW, Bai R, Duyster J, Delsol G, Allouche M.
    Oncogene; 2001 Nov 01; 20(50):7386-97. PubMed ID: 11704868
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti cancer effects of chemotherapy in vitro.
    Hsu FY, Zhao Y, Anderson WF, Johnston PB.
    Cancer Invest; 2007 Jun 01; 25(4):240-8. PubMed ID: 17612934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.